Pharmacodynamic studies
We are equipped with specialized instruments and devices, including flow cytometers, microplate readers, fluorescence microscopes, and PCR machines. These resources enable us to establish animal models for diseases affecting the tumor, cardiovascular, respiratory, metabolic, and urinary systems, and to conduct comprehensive, systematic preclinical studies on drug efficacy and mechanisms at multiple levels.
The pharmacodynamic study project is presented as follows:
We can custom-build disease-specific animal models tailored to different disease areas.
1) Liver disease models: alcoholic/non-alcoholic fatty liver, liver fibrosis, liver cirrhosis, hepatic ascites, etc., to support the evaluation of efficacy and safety of liver-targeted drugs.
2) Infectious Disease Models: We can construct various infectious disease models—including hepatitis B and bacterial infections—on demand, supporting in vivo efficacy validation of anti-infective drugs.
3) Cardiovascular disease models: atherosclerosis, myocardial infarction, cerebral embolism, coagulation disorders, neutropenia, thrombocytopenia, anemia, and more—catering to the multi-scenario research needs of cardiovascular drugs.
4) Disease models for respiratory system disorders: These models are suitable for common respiratory conditions such as pulmonary fibrosis, pulmonary embolism, and asthma, helping to elucidate the mechanisms and therapeutic effects of respiratory drugs.
5) Metabolic Disease Models: Diabetes, insulin resistance, obesity, hyperlipidemia (PCSK9-targeted drugs), and hyperuricemia—matching R&D scenarios for innovative metabolic drugs.
6) Urogenital disease models: drug-induced kidney injury, surgically induced kidney injury, renal insufficiency, etc., supporting safety and pharmacodynamic studies of urogenital drugs.
7) Immune-related disease models: arthritis, multiple sclerosis, in vivo neutralization assays for TNF-α-targeted drugs, and graft-versus-host disease (GVHD), all of which support the development of immunomodulatory drugs.
8) Tumor models: Subcutaneous xenograft tumors, orthotopic xenograft tumors, PTX models, and immune-reconstituted mouse tumor models—suitable for in vivo efficacy evaluation of different tumor-targeted drugs.
In vitro testing experiments: Accurately analyze drug mechanisms and offer a diverse range of in vitro testing services, elucidating the effects of drugs at the cellular and molecular levels. The project overview is as follows:
Cell proliferation inhibition assay, in vitro neutralization assay for TNF-α-targeted drugs, chick embryo angiogenesis inhibition assay, flow cytometry, in vitro antibacterial assay, cell viability and binding activity assays for PCSK9-targeted drugs, and ELISA assay.
 |  |
Rotary slicer | Pathological Diagnostic Microscopy System |
 |  |
Ultra-large tissue section | Canine whole-body tissue sections |
More fields
As an institution in Shaanxi Province that has obtained NMPA drug GLP certification and completed its qualification re-examination and scope expansion in 2024, Guorui Yinuo has built a “global + domestic” dual-compliance service capability in the pharmaceutical sector.
The one-stop service platform for veterinary drugs—GLP/GCP—is a specialized service provider that offers an integrated solution—from non-clinical evaluation to clinical trials and registration submission—aligned with both the Ministry of Agriculture and Rural Affairs’ GLP/GCP standards for veterinary drugs and the international OECD GLP standards, covering the entire R&D process for veterinary pharmaceuticals. At its core, this platform addresses the key pain points faced by companies, including long R&D cycles, high compliance barriers, and fragmented resources.
As the only organization in the Northwest region to have obtained OECD GLP certification in the pesticide field, Guorui Yinuo passed the international assessment with a zero-defect record. Relying on its compliance credentials, comprehensive technological capabilities across the entire value chain, and high-standard laboratory platform, Guorui Yinuo provides integrated solutions for global pesticide companies—from research and development all the way through registration.
Relying on the OECD GLP zero-defect certification qualification, chemical test data can be globally recognized and simultaneously comply with both domestic and international chemical regulatory requirements as well as relevant requirements of the Ministry of Ecology and Environment, efficiently supporting needs such as chemical registration and export declarations.
Shaanxi Guorui Xinchuang Medical Technology Co., Ltd. is an independent, third-party clinical preclinical safety evaluation research institution for medical devices. It was registered and established in June 2020 in the Airport New City and is currently the most comprehensive medical device safety evaluation institution in Northwest China. The company primarily provides product safety evaluation services to R&D enterprises specializing in Class II and Class III medical devices.
A full-process technology empowerment platform from target discovery to IND submission
Early Toxicity Prediction and Screening
Early toxicity screening is an essential and indispensable step in the new drug development process. Early termination of compounds that show no development potential can save sponsor substantial amounts of manpower, resources, and time. We offer sponsor comprehensive early toxicity screening services, including early genotoxicity assessment, early general toxicity assessment, and early reproductive and developmental toxicity assessment.
We are equipped with specialized instruments and devices, including flow cytometers, microplate readers, fluorescence microscopes, and PCR machines. These resources enable us to establish animal models for diseases affecting the tumor, cardiovascular, respiratory, metabolic, and urinary systems, and to conduct comprehensive and systematic preclinical studies on drug efficacy and mechanisms at multiple levels.
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681